Repository logo
 

Smart control lipid-based nanocarriers for fine-tuning gut hormone secretion.

Accepted version
Peer-reviewed

Loading...
Thumbnail Image

Change log

Abstract

Modulating the endogenous stores of gastrointestinal hormones is considered a promising strategy to mimic gut endocrine function, improving metabolic dysfunction. Here, we exploit mouse and human knock-in and knockout intestinal organoids and show that agents used as commercial lipid excipients can activate nutrient-sensitive receptors on enteroendocrine cells (EECs) and, when formulated as lipid nanocarriers, can bestow biological effects through the release of GLP-1, GIP, and PYY from K and L cells. Studies in wild-type, dysglycemic, and gut Gcg knockout mice demonstrated that the effect exerted by lipid nanocarriers could be modulated by varying the excipients (e.g., nature and quantities), the formulation methodology, and their physiochemical properties (e.g., size and composition). This study demonstrates the therapeutic potential of using nanotechnology to modulate release of multiple endogenous hormones from the enteroendocrine system through a patient-friendly, inexpensive, and noninvasive manner.

Description

Journal Title

Sci Adv

Conference Name

Journal ISSN

2375-2548
2375-2548

Volume Title

Publisher

American Association for the Advancement of Science (AAAS)

Rights and licensing

Except where otherwised noted, this item's license is described as Attribution 4.0 International
Sponsorship
Wellcome Trust (100574/Z/12/Z)
Wellcome Trust (220271/Z/20/Z)
MRC (MC_UU_00014/3)
MRC (MC_UU_00014/5)
Y.X. was a postdoctoral researcher at UCLouvain (Belgium) and University of Cambridge (United Kingdom) supported by the European Research Council (ERC), Wallonie-Bruxelles International (WBI) and Belgian FRS-FNRS (Fonds de la Recherche Scientifique). She is a researcher under grant National Nature Science Foundation of China Excellent Young Scholars Fund (Overseas) and General Program (82370860), the Fundamental Research Funds for the Central Universities (YJ202412) and Department of Science and Technology of Sichuan Province (24YFHZ0326). A.B. is a research associate from the Belgian FRS-FNRS (Fonds de la Recherche Scientifique). A.B. was supported by the FRS-FNRS (convention T.0013.19) and has received funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program (grant agreement No. 850997-NanoGut). P.D.C. is supported by the Belgian F.R.S.-FNRS (Fonds de la recherche scientifique) under grants The Excellence Of Science (EOS: 40007505), ARC (action de recherche concertée: ARC19/24-096) and La Caixa (NeuroGut). N.G. was a UK-MRC funded PhD student. Work in the Reimann/Gribble laboratory was further supported by grants from Wellcome (220271/Z/20/Z), the UK Medical Research Council (MC_UU_00014/3) and grants supporting core facilities (supported by the MRC [MRC_MC_UU_00014/5] and Wellcome Trust [100574/Z/12/Z]). D.J.D. is supported by CIHR grant 154321, a Banting and Best Diabetes Centre Chair in Incretin biology, and a Sinai Health Novo Nordisk Foundation fund in regulatory peptides.